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ABSTRACT
Introduction: Since the emergence of antiretroviral therapy, the survival of patients infected 
with human immunodeficiency virus has increased. Non-adherence to this therapy is directly 
related to treatment failure, which allows the emergence of resistant viral strains. Methods: A 
retrospective descriptive study of the antiretroviral dispensing records of 229 patients from 
the Center for Health Care, University Hospital, Federal University of Juiz de Fora, Brazil, 
was conducted between January and December 2009. Results: The study aimed to evaluate 
patient compliance and determine if there was an association between non-adherence and the 
therapy. Among these patients, 63.8% were men with an average age of 44.0 ± 9.9 years. The 
most used treatment was a combination of 2 nucleoside reverse transcriptase inhibitors with 1 
non-nucleoside reverse transcriptase inhibitor (55.5%) or with 2 protease inhibitors (28.8%). 
It was found that patients taking lopinavir/ritonavir with zidovudine and lamivudine had a 
greater frequency of inadequate treatment than those taking atazanavir with zidovudine and 
lamivudine (85% and 83.3%, respectively). Moreover, when the combination of zidovudine/
lamivudine was used, the patients were less compliant (χ2 = 4.468, 1 degree of freedom, p = 
0.035). Conclusions: The majority of patients failed to correctly adhere to their treatment; 
therefore, it is necessary to implement strategies that lead to improved compliance, thus 
ensuring therapeutic efficacy and increased patient survival. 
Keywords: Acquired immunodeficiency syndrome. Medication adherence. Anti-retroviral agents.
RESUMO
Introdução: A partir do surgimento da terapia antirretroviral, o paciente soropositivo teve 
sua sobrevida aumentada. A não adesão a essa terapia está relacionada diretamente à falência 
terapêutica, a qual propicia o aparecimento de cepas virais mais resistentes. Métodos: Foi 
realizado um estudo retrospectivo e descritivo dos registros de dispensação de antirretrovirais 
de 229 pacientes do Centro de Atenção à Saúde do Hospital Universitário da Universidade 
Federal de Juiz de Fora, no período de janeiro a dezembro de 2009. Resultados: Tal estudo 
teve por objetivo avaliar a adesão do paciente ao tratamento e se houve associação entre a 
não adesão e a terapêutica. Desses pacientes, 63,8% eram do sexo masculino e apresentavam 
idade média de 44,0 ± 9,9 anos. Foram realizados 28 esquemas terapêuticos diferentes. Dentre 
esses, os mais utilizados foram aqueles que combinavam 2 inibidores da transcriptase reversa 
análogos de nucleosídeos/nucleotídeos com 1 inibidor da transcriptase reversa não análogo de 
nucleosídeo (55,5%) ou com 2 inibidores de protease (28,8%). Foi verificado que os pacientes 
em uso de lopinavir/ritonavir ou atazanavir associados à zidovudina e lamivudina apresentaram 
maiores frequências de tratamento considerado inadequado (85% e 83,3%, respectivamente). 
Além disso, quando a combinação zidovudina/lamivudina esteve presente no esquema 
medicamentoso, os pacientes aderiram menos ao tratamento (χ2 = 4,468; grau de liberdade = 1; 
p = 0,035). Conclusões: A maioria dos pacientes realizava tratamento considerado inadequado. 
Portanto, é necessário implementar estratégias que conduzam à melhoria da adesão ao 
tratamento, a fim de garantir eficácia terapêutica e aumento da sobrevida do paciente.
Palavras-chaves: Síndrome da imunodeficiência adquirida. Adesão à medicação. Agentes 
antirretrovirais.
Treatment w ith antiretrov iral  drugs of 
people infected with Human Immunodeficiency 
Virus/Acquired Immunodeficiency Syndrome 
(HIV/AIDS) associated with the prevention and 
control of infection have improved significantly 
changes in mortality rates and life expectancy among 
HIV-positive individuals1 (esta frase foi modificada). 
For any therapy to succeed, it is necessary that 
patients are aware of the importance of their 
adherence to their pharmacological treatment2. 
The incorrect use of antiretroviral drugs is related 
to treatment failure by the emergence of viral strains 
that are resistant to the drugs used3.
According to the Brazilian Ministry of Health, 
adherence may be construed as a multifactorial and 
dynamic aspect that involves physical, psychological, 
social, cultural, and behavioral factors. It requires the 
integration of the patient, health professionals, and 
social network by establishing the responsibilities of 
each in the process and helping to promote self-care4.
Low adherence to drug therapy is a public health 
problem because it increases the risk of developing 
drug resistance, and adverse effects may occur 
following the abrupt cessation of therapy or the 
occurrence of toxicity by drug overuse5,6.
Dias7 and Faustino and Seidl8 considered that the 
complexity of the regimen and the low educational 
level of patients decrease the ability of patients to 
cope with treatment difficulties, which can lead 
to rejection of their seropositivity. Moreover, the 
adverse effects of antiretroviral medications, poor 
patient relationship with health professionals, 
difficulties in adapting to the daily routine of drug 
therapy, and alcohol and drug use are also considered 
risk factors for poor adherence to drug treatment.
Non-adherence can be found in several forms 
and highlights the failure to fully or partially 
follow the prescriptions and the interruption or 
discontinuation of treatment, as well as excessive 
drug intake5. Although there is no standard for 
assessing adherence to ART, there are several 
approaches that may assist in its evaluation. These 
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TABLE 1 – Patient adherence to ART by age group at the Center for Health 
Care, University Hospital, Federal University of Juiz de Fora.
 Appropriate  Inadequate 
Age (years) treatment % treatment %
< 30 years 8.3 91.7
31–50 29.2 70.8
>50 25.0 75.0
ART: antiretroviral therapy; χ2: 2,623; degrees of freedom: 2; p = 0.269; n = 229.
TABLE 2 - Distribution of patients on ART according to pharmacological 
therapy.
Treatment Number Percentage
Efavirenz + (zidovudine + lamivudine) 78 34.1
Lopinavir/ritonavir + (zidovudine + lamivudine) 40 17.5
Efavirenz + lamivudine + tenofovir 19 8.3
Nevirapine + (zidovudine + lamivudine) 18 7.9
Lamivudine + lopinavir/ritonavir + tenofovir 15 6.6
Atazanavir + (zidovudine + lamivudine) 12 5.2
Other therapies 47 20,5
Total 229 100.0
ART: antiretroviral therapy.
approaches include self-reported assessments through medical 
records, number of pills distributed, drug plasma concentration 
measurements, and dispensing pharmacy records9.
In the City of Juiz de Fora, Minas Gerais, there are 2 antiretroviral 
dispensing units (ADUs): the Serviço de Assistência Especializada de 
Juiz de Fora (Specialized Care Unit in Juiz de Fora) and the Centro de 
Atenção à Saúde do Hospital Universitário, Universidade Federal de Juiz 
de Fora (Center for Health Care at the University Hospital, Federal 
University of Juiz de Fora) (HU/CAS/UFJF). Within the context 
of adherence to ART, this study aimed to evaluate the factors that 
affect adherence, the focus on drug therapy, and the prevalence of 
inadequate treatment (i.e., irregular adherence and dropout).
We conducted a retrospective and descriptive study that analyzed 
the antiretroviral drug distribution log from the HU/CAS/UFJF ADU.
All patients seen in this ADU were included. They comprised 229 
patients who were assisted between January and December 2009. The 
inclusion criteria were (1) age over 18 years and (2) maintenance 
on the same drug regimen during this period. We excluded pregnant 
women and patients who died during the study period.
From the model, which was adapted from Gomes et al.9, patients 
that did not adhere to therapy or who did not acquire their drugs 
at the appropriate time were classified as receiving inadequate 
treatment, which could be described as: a) irregular adherence, i.e., 
the interval between collecting medication was >34 days, considering 
that the drugs are distributed for 30 days; and b) treatment dropout, 
i.e., not collecting medication for >2 months.
We also analyzed gender, age, and current drug regimen. For 
patients receiving inappropriate treatment, we evaluated their 
pharmacological therapy. We checked if there was an association 
between treatment compliance and drug therapy.
Variables were evaluated with the aid of the Statistical Package for 
Social Sciences, version 14.0. Association analyses (chi-square test, 
χ2) were made from the type of treatment (adequate or inadequate) 
and the other variables. The significance value was 0.05.
Ethical considerations
This project was approved by the Ethics Committee of the Federal 
University of Juiz de Fora (No. 299/2009, CAAE 0187.0.180.000-09).
We evaluated 229 patients undergoing pharmacological 
treatment for HIV between January and December 2009. Of this 
total population, 63.8% (n = 146) were male and 36.2% (n = 83) 
were female, with an average age of 44.0 ± 9.9 years.
Regarding the assessment of medication adherence, 72.9% 
(n = 167) of patients received inappropriate treatment, characterized 
by irregular adherence or therapy abandonment, while 27.1% 
(n = 62) underwent appropriate treatment and were considered 
adherent to the prescribed drug therapy.
Gender analysis, when used as an adherence function to 
treatment, showed that 73.3% (n = 107) of men had inadequate 
treatment, while for females, this figure was 72.3% (n = 60); no 
statistically significant difference was observed (χ2 < 0.001, degrees 
of freedom = 1, p = 0.993).
No association was found between adherence and patient age 
(Table 1).
Twenty-eight different drug combinations were found, and 
of those, 11 consisted of zidovudine/lamivudine (AZT/3TC) 
in combination with other drugs. In addition, 19 of them were 
triple combinations, 7 with a combination of 4 drugs, and 2 with 
5 combinations. The most used therapy was the combination of 
efavirenz (EFV) and AZT/3TC (34.1%, n = 78), followed by 
lopinavir/ritonavir (LPV/r) combined with AZT/3TC (17.5%, 
n = 40). Other frequently used therapies were EFV plus 3TC and 
tenofovir (TDF) (8.3%, n = 19), nevirapine (NVP) in combination 
with AZT/3TC (7.9%, n = 18), 3TC combined with LPV/TDF 
(6.6%, n = 15), and atazanavir (ATV) with AZT/3TC (5.2%, n = 12) 
(Table 2). The other 22 therapies were prescribed to <10 patients, 
and among them, 14 were used for only 1 patient.
In 55.5% (n = 127) of cases, the patients used a combination 
of 2 reverse transcriptase inhibitors, nucleoside/nucleotide 
analogs (NRTIs) (zidovudine, lamivudine, tenofovir, stavudine, 
didanosine, or abacavir) and 1 non-nucleoside analog reverse 
transcriptase inhibitor (NNRTI) (efavirenz or nevirapine). The 
combination of 2 NRTIs and 2 protease inhibitors (PI) (lopinavir, 
ritonavir, atazanavir, saquinavir, or indinavir) was used in 28.8% 
(n = 69) of the therapies.
From the patients using the combination of LVP/r AZT/3TC, 
85% (n = 34) were considered to be receiving inadequate treatment 
(Table 3).
The majority of the patients (n = 159, 66.4%) received AZT/3TC 
in combination with another drug. The compliance for these drugs 
can be seen in Table 4.
Data analysis showed that when AZT/3TC was used, the patients 
adhered less to the therapy; however, when AZT or 3TC was used 
separately, it did not affect adherence.
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TABLE 3 - Distribution of patients who were undergoing ART and had 
inadequate treatment due to combination therapy.
 Patients with inadequate 
 treatment
Treatment n %
Lopinavir/ritonavir + (zidovudine + lamivudine) 34 85.0
Atazanavir + (zidovudine + lamivudine) 10 83.3
Efavirenz + (zidovudine + lamivudine) 59 75.6
Nevirapine + (zidovudine + lamivudine) 13 72.2
Efavirenz + lamivudine + tenofovir 12 63.2
Lamivudine + lopinavir/ritonavir + tenofovir 10 63.2
Others* 64 61.7
Total 167 -
ART: antiretroviral therapy. *drug combinations with a prescription administered 
to <10 patients.
TABLE 4 - Patient adherence to ART containing AZT+3TC.
 Adequate Inadequate 
 treatment treatment Total
 n % n % n %
AZT+3TC absent 26  11.4 44  19.2 70 30.6
AZT+3TC present 36  15.7 123  53.7 159 69.4
Total 62 27.1 167 72.9 229 100.0
ART: antiretroviral therapy; AZT: zidovudine; 3TC: lamivudine. χ2: 4,468 
(with Yates correction for continuity); degrees of freedom: 1; p = 0.035; n = 229.
DISCUSSION
With the increased life expectancy of HIV-positive patients 
after the development of ART1, new challenges have emerged 
in an attempt to improve the quality of their lives. Among these 
new concerns is the need for their reintegration into society, the 
promotion of healthy habits, and the concern in making the patient 
and society understand the rights of HIV-positive persons with 
respect to their sexuality and parenthood. Furthermore, knowledge 
has to be provided about how to cope with the adverse effects of 
treatment, their adaptation to the treatment regimen, the continuous 
evaluation of infection, and properly treating co-infections such as 
hepatitis and tuberculosis10.
Data analysis in this study showed that out of the 229 patients, 
63.8% were male and 36.2% female, i.e., 1.8 men for every woman. 
This finding supports the results of Carmody et al.11, Carrieri et al.12, 
Gomes et al.9, and Carvalho et al.13
The average age of the patients found in this study was 44.0 ± 
9.9 years, similar to the findings of Pinto Neto et al.14 (42.76 ± 10.29 
years). However, Carrieri et al.12 and Carvalho et al.13 reported an 
average age of 37 years and 36.5 years, respectively, while Gomes 
et al.9 reported that 53.2% of their patients were younger than 35 
years. These results reinforce the importance of local epidemiological 
studies, since knowledge of patient characteristics is crucial for 
effective health promotion campaigns.
It was observed that 72.9% (n = 167) of patients received 
inappropriate treatment, characterized by their irregular adherence 
to therapy or abandonment. This finding differs from those obtained 
by Saldanha, Andrade, and Beck15, who found a high rate of treatment 
adherence (72%), and by Seidl et al.16, where the compliance rate 
reached 72.3%. However, in these studies with high drug compliance, 
there was a pharmacist intervention, which, when the present study 
was performed, was not available at the participating health centers.
While this study did not find a significant difference in the 
evaluation of adherence to therapy by gender, Nachega et al.17 found 
a higher rate of adherence in women, while Carmody et al.11 found 
an association between non-adherence and female gender.
Although no association was observed between age group and 
adherence to therapy, we found that people aged younger than 30 
years were more prone to irregular adherence or non-adherence to 
treatment (91.7%). This finding is contrary to the literature, where it 
is observed that the higher the age, the higher the rate of adherence 
to therapy, with an age between 25 and 34 years considered as a risk 
factor for non-adherence17,18. However, we present a limitation of 
the current study here in that we did not know the income or the 
educational level of the patients, which probably influenced drug 
compliance, and the lack of this fit could be the cause for this absence 
of significance.
In this study, we found that 28 different drug combinations 
had been used for the study population. However, 6 combinations 
were used in 59.5% of patients, which showed that some treatments 
are prescribed more often than others. Most therapies were triple 
(n = 18); 7 consisted of 4 drugs and 2 with 5 combinations. Gir 
Vaichulonis and Oliveira19 found similar data, since 84.5% of their 
patients were using a regimen of up to 3 medications. Therapies 
involving a combination of more than 4 drugs are used in order to 
achieve immune rescue or as a resource for those patients whose 
treatment has already encountered some kind of resistance.
It was found that 55.5% of seropositive individuals were using 
a combination of 2 NRTIs and an NNRTI. This combination of a 
PI with 2 NRTIs, which was also clearly observed in this study, is a 
guideline of the Brazilian Ministry of Health for the initial therapy 
against HIV20. Furthermore, a combination of 2 NRTIs and 2 PIs 
was used in 28.8% of cases, in accordance with the guideline of the 
Ministry of Health, which states that when replacing an NNRTI, a 
PI should be used in combination with ritonavir, which is also a drug 
of the same class20.
The most common combination of 2 NRTIs and an NNRTI 
was AZT/3TC with EFV (34.1%). Likewise, in the study of Gomes 
et al.9, 30.7% of patients used this combination therapy. However, 
regarding the combination of 2 NRTIs and a PI, Gomes et al.9 
found that 23.5% of patients used the combination of nelfinavir 
and AZT/3TC, whereas in the present study, lopinavir/ritonavir 
(LPV/r) combined with AZT/3TC was the most common NRTI-IP 
combination (17.5%).
Carrieri et al.12 observed that the presence of a PI in combination 
therapy was one of the factors that influenced noncompliance. This 
might be explained by the fact that treatments without a PI are simpler 
and have less adverse effects than other therapies. However, Gomes et 
al.9 found significant results concerning combined therapy without a 
PI and non-adherence to treatment, contradicting the previous study. 
In the present study, those combinations containing LPV/r or ATV 
and AZT plus 3TC showed higher rates of inadequate treatment 
(85% and 83.3%, respectively).
Among the pharmacological combinations analyzed5, they had 
a pair NRTI AZT/3TC between drugs used in the therapy. The use 
of AZT/3TC in the majority of the combinations in this study can 
be attributed to the fact that the Ministry of Health recommends 
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